Pubblicazioni

Documenti scaricabili

Titolo	Data	Dimensioni	Download
Documento di indirizzo dell’Associazione Italiana per lo Studio del Fegato per l’uso razionale dei farmaci anti-HCV disponibili in Italia 710 download	24 Settembre 2018	1.51 MB	Download
Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1–4 in Italy 993 download	25 Luglio 2018	1.36 MB	Download
Centri partecipanti al programma di cross-validazione per i test di resistenza sui geni target della terapia anti-HCV (NS3, NS5A, NS5B) 862 download	16 Luglio 2018	58.48 KB	Download

Pubblicazioni VIRONET C ONLUS

Di Maio VC, Barbaliscia S, Teti E, Fiorentino G, Milana M, Paolucci S, Pollicino T, Morsica G, Starace M, Bruzzone B, Gennari W, Micheli V, Yu La Rosa K, Foroghi L, Calvaruso V, Lenci I, Polilli E, Babudieri S, Aghemo A, Raimondo G, Sarmati L, Coppola N, Pasquazzi C, Baldanti F, Parruti G, Perno CF, Angelico M, Craxì A, Andreoni M, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network Group (Vironet C). Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network Vironet-C. Liver Int. 2021 Jan 26. doi: 10.1111/liv.14797. Online ahead of print. PMID: 33497016
https://www.ncbi.nlm.nih.gov/pubmed/33497016
Dietz J, Di Maio VC, de Salazar A, Merino D, Vermehren J, Paolucci S, Kremer AE, Lara M, Pardo MR, Zoller H, Degasperi E, Peiffer KH, Sighinolfi L, Téllez F, Graf C, Ghisetti V, Schreiber J, Fernández-Fuertes E, Boglione L, Muñoz-Medina L, Stauber R, Gennari W, Figueruela B, Santos J, Lampertico P, Zeuzem S, Ceccherini-Silberstein F, García F, Sarrazin C; HCV Virology Italian Resistance Network (VIRONET-C) collaborators; Spanish GEHEP-004 Collaborators; Members of the German HCV resistance study group. Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. J Hepatol. 2020 Nov 19:S0168-8278(20)33770-3. doi: 10.1016/j.jhep.2020.11.017. Online ahead of print. PMID: 33220331
https://www.ncbi.nlm.nih.gov/pubmed/33220331
de Salazar A, Dietz J, di Maio VC, Vermehren J, Paolucci S, Müllhaupt B, Coppola N, Cabezas J, Stauber RE, Puoti M, Arenas Ruiz Tapiador JI, Graf C, Aragri M, Jimenez M, Callegaro A, Pascasio Acevedo JM, Macias Rodriguez MA, Rosales Zabal JM, Micheli V, Garcia Del Toro M, Téllez F, García F, Sarrazin C, Ceccherini-Silberstein F; GEHEP-004 cohort, the European HCV Resistance Study Group and the HCV Virology Italian Resistance Network (VIRONET C). Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentavir regimen. J Antimicrob Chemother. 2020 Nov 1;75(11):3349-3358. doi: 10.1093/jac/dkaa304. PMID: 32772078
https://www.ncbi.nlm.nih.gov/pubmed/32772078
Bertoli A, Sorbo MC, Aragri M, Lenci I, Teti E, Polilli E, Di Maio VC, Gianserra L, Biliotti E, Masetti C, Magni CF, Babudieri S, Nicolini LA, Milana M, Cacciatore P, Sarmati L, Pellicelli A, Paolucci S, Craxì A, Morisco F, Palitti VP, Siciliano M, Coppola N, Iapadre N, Puoti M, Rizzardini G, Taliani G, Pasquazzi C, Andreoni M, Parruti G, Angelico M, Perno CF, Cento V, Ceccherini-Silberstein F1; HCV Virology Italian Resistance Network (VIRONET-C). Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. Sci Rep. 2018 Jun 12;8(1):8988.
https://www.ncbi.nlm.nih.gov/pubmed/29895871
Di Maio VC, Cento V, Aragri M, Paolucci S, Pollicino T, Coppola N, Bruzzone B, Ghisetti V, Zazzi M, Brunetto M, Bertoli A, Barbaliscia S, Galli S, Gennari W, Baldanti F, Raimondo G, Perno CF, Ceccherini-Silberstein F; HCV Virology Italian Resistance Network (VIRONET-C). Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? J Hepatol. 2018 Mar;68(3):597-600. doi: 10.1016/j.jhep.2017.09.008. Epub 2017 Sep20. PubMed PMID: 28939133.
https://www.ncbi.nlm.nih.gov/pubmed/28939133
Cento V, Aragri M, Teti E, Polilli E, Bertoli A, Foroghi L, Barbaliscia S, Di Maio VC, Pieri A, Pace Palitti V, Sarmati L, Parruti G, Andreoni M, Perno CF, Ceccherini-Silberstein F. Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study. J Antimicrob Chemother. 2017 Dec 1;72(12):3420-3424. doi: 10.1093/jac/dkx302. PubMed PMID: 28961921.
https://www.ncbi.nlm.nih.gov/pubmed/28961921
Di Maio VC, Cento V, Di Paolo D, Aragri M, De Leonardis F, Tontodonati M, Micheli V, Bellocchi MC, Antonucci FP, Bertoli A, Lenci I, Milana M, Gianserra L, Melis M, Di Biagio A, Sarrecchia C, Sarmati L, Landonio S, Francioso S, Lambiase L, Nicolini LA, Marenco S, Nosotti L, Giannelli V, Siciliano M, Romagnoli D, Pellicelli A, Vecchiet J, Magni CF, Babudieri S, Mura MS, Taliani G, Mastroianni C, Vespasiani-Gentilucci U, Romano M, Morisco F, Gasbarrini A, Vullo V, Bruno S, Baiguera C, Pasquazzi C, Tisone G, Picciotto A, Andreoni M, Parruti G, Rizzardini G, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. J Antimicrob Chemother. 2016 Mar;71(3):739-50. doi: 10.1093/jac/dkv403. Epub 2015 Dec 17. PubMed PMID: 26679249.
https://www.ncbi.nlm.nih.gov/pubmed/26679249
Cento V, Barbaliscia S, Lenci I, Ruggiero T, Magni CF, Paolucci S, Babudieri S, Siciliano M, Pasquazzi C, Ciancio A, Perno CF, Ceccherini-Silberstein F; HCV retreatment team VIRONET-C study group. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life. Clin Microbiol Infect. 2017 Oct;23(10):777.e1-777.e4. doi: 10.1016/j.cmi.2017.04.005. Epub 2017 Apr 12. PubMed PMID: 28412381.
https://www.ncbi.nlm.nih.gov/pubmed/?term=ceccherini+silberstein+cento+lenci+optimal
Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E, Bertoli A, Antonucci F, Bellocchi MC, Micheli V, Masetti C, Landonio S, Francioso S, Santopaolo F, Pellicelli AM, Calvaruso V, Gianserra L, Siciliano M, Romagnoli D, Cozzolongo R, Grieco A, Vecchiet J, Morisco F, Merli M, Brancaccio G, Di Biagio A, Loggi E, Mastroianni CM, Pace Palitti V, Tarquini P, Puoti M, Taliani G, Sarmati L, Picciotto A, Vullo V, Caporaso N, Paoloni M, Pasquazzi C, Rizzardini G, Parruti G, Craxì A, Babudieri S, Andreoni M, Angelico M, Perno CF, Ceccherini-Silberstein F; HCV Italian Resistance Network Study Group. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017 Apr;37(4):514-528. doi: 10.1111/liv.13327. Epub 2017 Jan 20. PubMed PMID: 28105744.
https://www.ncbi.nlm.nih.gov/pubmed/28105744

Altre pubblicazioni utili

2020

Salpini R, Piermatteo L, Battisti A, Colagrossi L, Aragri M, Yu La Rosa K,Bertoli A, Saccomandi P, Lichtner M, Marignani M, Maylin S, Delaugerre C, MoriscoF, Coppola N, Marrone A, Iapadre N, Cerva C, Aquaro S, Angelico M, Sarmati L,Andreoni M, Verheyen J, Ceccherini-Silberstein F, Levrero M, Perno CF, Belloni L,Svicher V. A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition in Vitro. Viruses. 2020 Feb 23;12(2):251.
https://www.ncbi.nlm.nih.gov/pubmed/32102257

Aragri M, Milana M, Di Maio VC, Lenci I, Carioti L, Perno CF, Svicher V, Angelico M, Ceccherini-Silberstein F. Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance. Clin Microbiol Infect. 2020 Sep;26(9):1266-1268.
https://www.ncbi.nlm.nih.gov/pubmed/32240711

Salpini R, Malagnino V, Piermatteo L, Mulas T, Alkhatib M, Scutari R, Teti E, Cerva C, Yu La Rosa K, Brugneti M, Bertoli A, Rossi B, Holzmayer V, Gersch J, Kuhns M, Cloherty G, Ceccherini-Silberstein F, Perno CF, Iannetta M, Andreoni M, Sarmati L, Svicher V. Cryptic HBV Replicative Activity Is Frequently Revealed in Anti-HBc-Positive/HBsAg-Negative Patients with HIV Infection by Highly Sensitive Molecular Assays, and Can Be Predicted by Integrating Classical and Novel Serological HBV Markers. Microorganisms. 2020 Nov; 8(11): 1819.
https://www.ncbi.nlm.nih.gov/pubmed/33218205

Salpini R, Battisti A, Piermatteo L, Carioti L, Anastasiou OE, Gill US, Di Carlo D, Colagrossi L, Duca L, Bertoli A, Yu La Rosa K, Fabeni L, Iuvara A, Malagnino V, Cerva C, Lichtner M, Mastroianni CM, De Sanctis GM, Paoloni M, Marignani M, Pasquazzi C, Iapadre N, Parruti G, Vecchiet J, Sarmati L, Andreoni M, Angelico M, Grelli S, Kennedy PT, Verheyen J, Aquaro S, Ceccherini-Silberstein F, Perno CF, Svicher V. Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection. Emerg Microbes Infect. 2020; 9(1): 928–939.
https://www.ncbi.nlm.nih.gov/pubmed/32312174

Svicher V, Salpini R, Piermatteo L, Carioti L, Battisti A, Colagrossi L, Scutari R, Surdo M, Cacciafesta V, Nuccitelli A, Hansi N, Ceccherini Silberstein F, Perno CF, Gill US, Kennedy PTF. Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B. Gut. 2020 Dec 21:gutjnl-2020-323300.
https://www.ncbi.nlm.nih.gov/pubmed/33402415

Nguyen D, Smith D, Vaughan-Jackson A, Magri A, Barnes E, Simmonds P. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia. J Hepatol. 2020;73:794–799.
https://www.ncbi.nlm.nih.gov/pubmed/3270499

Papaluca T, Roberts SK, Strasser SI, et al. Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa1318
https://www.ncbi.nlm.nih.gov/pubmed/32887983

Singh AD, Maitra S, Singh N, et al. Systematic review and meta-analysis: impact of baseline resistance-associated substitutions on the efficacy of glecaprevir/pibrentasvir among chronic hepatitis C patients. Aliment Pharmacol Ther. 2020;1–15. doi:10.1111/apt.15633
https://www.ncbi.nlm.nih.gov/pubmed/31943236

Soria A, Fava M, Bernasconi DP, et al. Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort. Liver Int. 2020;40:769–777.
https://www.ncbi.nlm.nih.gov/pubmed/31970845
EASL Recommendations on Treatment of Hepatitis C 2020
https://www.ncbi.nlm.nih.gov/pubmed/32956768

2019

Salpini R, Battisti A, Colagrossi L, Di Carlo D, Fabeni L, Piermatteo L, Cerva C, Lichtner M, Mastroianni C, Marignani M, Maylin S, Delaugerre C, Morisco F, Coppola N, Marrone A, Angelico M, Sarmati L, Andreoni M, Perno CF, Ceccherini-Silberstein F, Svicher V. A snapshot of virological presentation and outcome of immunosuppression-driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection. J Viral Hepat. 2019 Jul;26(7):846-855.
https://www.ncbi.nlm.nih.gov/pubmed/30974483

Salpini R, Surdo M, Cortese MF, Palumbo GA, Carioti L, Cappiello G, Spanò A, Trimoulet P, Fleury H, Vecchiet J, Pasquazzi C, Mirabelli C, Scutari R, Sacco A, Alkhatib M, Missale G, Francioso S, Sarmati L, Andreoni M, Angelico M, Ceccherini-Silberstein F, Levrero M, Perno CF, Belloni L, Svicher V. The novel HBx mutation F30V correlates with HCC in vivo, reduces HBV replicative efficiency and enhances anti-apoptotic activity of HBx N-terminus in vitro. Clin Microbiol Infect. 2019 Jul;25(7):906.e1-906.e7.
https://www.ncbi.nlm.nih.gov/pubmed/30472417

Hedskog C, Parhy B, Chang S, et al. Identification of 19 Novel Hepatitis C Virus Subtypes—Further Expanding HCV Classification. Open Forum Infect Dis. 2019;6.
https://www.ncbi.nlm.nih.gov/pubmed/30949527

Bagaglio S, Messina E, Hasson H, Galli A, Uberti-Foppa C, Morsica G. Geographic distribution of HCV-GT3 subtypes and naturally occurring resistance associated substitutions. Viruses. 2019. doi:10.3390/v11020148
https://www.ncbi.nlm.nih.gov/pubmed/30754682

International Committee on Taxonomy of Viruses (ICTV).
https://talk.ictvonline.org/ictv_wikis/flaviviridae/w/sg_flavi/56/hcv-classification

Pawlotsky JM. Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures. Semin Liver Dis. 2019;39:354–368.
https://www.ncbi.nlm.nih.gov/pubmed/31041789

McPhee F. Developments in the treatment of HCV genotype 3 infection. Expert Rev Anti Infect Ther. 2019;17:775–785.
https://www.ncbi.nlm.nih.gov/pubmed/31584833

Papaluca T, O’Keefe J, Bowden S, et al. Prevalence of baseline HCV NS5A resistance associated substitutions in genotype 1a, 1b and 3 infection in Australia. J Clin Virol. 2019;120:84–87 .
https://www.ncbi.nlm.nih.gov/pubmed/31606586

Viganò M, Andreoni M, Perno CF, Craxì A, Aghemo A, Alberti A, Andreone P, Babudieri S, Bonora S, Brunetto MR, Bruno R, Bruno S, Calvaruso V, Caporaso N, Cartabellotta F, Ceccherini-Silberstein F, Cento V, Ciancio A, Colombatto P, Coppola N, Di Marco V, Di Perri G, Fagiuoli S, Gaeta GB, Gasbarrini A, Lampertico P, Pellicelli A, Prestileo T, Puoti M, Raimondo G, Rizzardini G, Taliani G, Zignego AL. Real life experiences in HCV management in 2018. Expert Rev AntiInfect Ther. 2019 Feb;17(2):117-128. IF 1.87
https://www.ncbi.nlm.nih.gov/pubmed/30582384

Sorbo MC, Carioti L, Bellocchi MC, Antonucci F, Sforza D, Lenci I, Ciancio Manuelli M, Armenia D, De Leonardis F, Milana M, Manzia TM, Angelico M, Tisone G, Cento V, Perno CF, Ceccherini-Silberstein F. HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma. Liver Int. 2019 Oct;39(10):1986-1998. IF 5.542
https://www.ncbi.nlm.nih.gov/pubmed/31172639

Bellocchi MC, Aragri M, Carioti L, Fabeni L, Pipitone RM, Brancaccio G, Sorbo MC, Barbaliscia S, Di Maio VC, Bronte F, Grimaudo S, Mazzucco W, Frigeri F, Cantone M, Pinto A, Perno CF, Craxì A, Gaeta GB, Di Marco V, Ceccherini-Silberstein F. NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients. Cells. 2019 Jul 2;8(7). IF 5.656
https://www.ncbi.nlm.nih.gov/pubmed/31269695

Smith D, Magri A, Bonsall D, et al. Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors. Hepatology. 2019. doi:10.1002/hep.29837.
https://www.ncbi.nlm.nih.gov/pubmed/29425396

Childs K, Davis C, Cannon M, et al. Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C. J Hepatol. 2019;71:1099–1105.
https://www.ncbi.nlm.nih.gov/pubmed/31400349

Fourati S, Rodriguez C, Hézode C, et al. Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r. Hepatology. 2019;69.
https://www.ncbi.nlm.nih.gov/pubmed/30125371

Llaneras J, Riveiro-Barciela M, Lens S, et al. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. J Hepatol. 2019. doi:10.1016/j.jhep.2019.06.002
https://www.ncbi.nlm.nih.gov/pubmed/31203153

2018

Leone S, Shanyinde M, Cozzi Lepri A, Lampe FC, Caramello P, Costantini A, Giacometti A, De Luca A, Cingolani A, Ceccherini Silberstein F, Puoti M, Gori A, d’Arminio Monforte A; ICONA Foundation Cohort Study. Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study. Eur J Clin Microbiol Infect Dis. 2018 May;37(5):871-881
https://www.ncbi.nlm.nih.gov/pubmed/29318459

Guardigni V, Cento V, Ianniruberto S, Badia L, Aragri M, Conti M, Perno CF, Viale P, Ceccherini-Silberstein F, Verucchi G. HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals. Infection. 2018 Oct;46(5):717-720
https://www.ncbi.nlm.nih.gov/pubmed/29804205

Colagrossi L, Salpini R, Scutari R, Carioti L, Battisti A, Piermatteo L, Bertoli A, Fabeni L, Minichini C, Trimoulet P, Fleury H, Nebuloso E, De Cristofaro M, Cappiello G, Spanò A, Malagnino V, Mari T, Barlattani A, Iapadre N, Lichtner M, Mastroianni C, Lenci I, Pasquazzi C, De Sanctis GM, Galeota Lanza A, Stanzione M, Stornaiuolo G, Marignani M, Sarmati L, Andreoni M, Angelico M, Ceccherini-Silberstein F, Perno CF, Coppola N, Svicher V. HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets. Viruses. 2018 Jul 9;10(7).
https://www.ncbi.nlm.nih.gov/pubmed/29987240

Popping S, Cento V, García F, Ceccherini-Silberstein F, Seguin-Devaux C, Vijver DA, Boucher CA. The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C. J Virus Erad. 2018 Jul 1;4(3):179-181.
https://www.ncbi.nlm.nih.gov/pubmed/30050681

Ceccherini-Silberstein F, Cento V, Di Maio VC, Perno CF, Craxì A. Viral resistance in HCV infection. Curr Opin Virol. 2018 Oct;32:115-127 https://www.ncbi.nlm.nih.gov/pubmed/30439589
Borgia SM, Hedskog C, Parhy B, et al. Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes. J Infect Dis. 2018. doi:10.1093/infdis/jiy401
https://www.ncbi.nlm.nih.gov/pubmed/29982508

Andreoni M, Babudieri S, Bruno S, et al.: Current and future challenges in HCV: insights from an Italian experts panel. Infection. 2018 Apr;46(2):147-163.
https://www.ncbi.nlm.nih.gov/pubmed/29098647

Asselah T, Bourgeois S, Pianko S, et al.: Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis. Liver Int 2018 Mar, 38:443–450.
https://www.ncbi.nlm.nih.gov/pubmed/28756625

Documento di indirizzo dell’Associazione Italiana per lo Studio del Fegato per l’uso razionale dei farmaci anti-HCV disponibili in Italia (aggiornamento 20 giugno 2018).
http://www.webaisf.org/pubblicazioni/documento-aisf-hcv-2017.aspx

Bruzzone B, Canepa P, De Rosa G, et al.: Correct Identification of Dual HCV Infections in HIV/HCV CoInfected Patients. AIDS Res Hum Retroviruses. 2018 Apr;34(4):325-326.
https://www.ncbi.nlm.nih.gov/pubmed/29314861

Calvaruso V, Cabibbo G, Cacciola I, et al.: Incidence of Hepatocellular Carcinoma in Patients with HCV-associated Cirrhosis Treated with Direct-Acting Antiviral Agents. Gastroenterology. 2018 Apr 12. pii: S0016-5085(18)30441-4.
https://www.ncbi.nlm.nih.gov/pubmed/29655836

Calvaruso V, Petta S, Craxì A.: Is global elimination of HCV realistic? Liver Int. 2018 Feb; 38 Suppl 1:40-46.
https://www.ncbi.nlm.nih.gov/pubmed/?term=Is+global+elimination+of+HCV+realistic%3F

Calvaruso V, Ferraro D, Licata A, et al.: HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals. J Viral Hepat. 2018 Jan;25(1):72-79.
https://www.ncbi.nlm.nih.gov/pubmed/28703895

Camus G, Han B, Asselah T, et al.: Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4. J Viral Hepat 2018 Feb, 25:134–143.
https://www.ncbi.nlm.nih.gov/pubmed/?term=camus+han+asselah

Caudai C, Materazzi A, Saladini F, et al.: Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy. Clin Microbiol Infect. 2018 Mar;24(3):308.e5-308.e8.
https://www.ncbi.nlm.nih.gov/pubmed/28811242

de Leuw P, Stephan C: Protease inhibitor therapy for hepatitis C virus-infection. Expert Opin Pharmacother 2018 Apr, 19:577–587.
https://www.ncbi.nlm.nih.gov/pubmed/29595065

Dietz J, Susser S, Vermehren J, et al.: Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. Gastroenterology 2018 Mar, 154:976–988.
https://www.ncbi.nlm.nih.gov/pubmed/29146520

EASL Recommendations on Treatment of Hepatitis C 2018. JHepatol 2018 Apr, doi:10.1016/j.jhep.2018.03.026.
https://www.ncbi.nlm.nih.gov/pubmed/29650333

Harrington PR, Komatsu TE, Deming DJ, et al.: Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives. Hepatology 2018 Jun, 67:2430–2448.
https://www.ncbi.nlm.nih.gov/pubmed/29194682

Hezode C, Reau N, Svarovskaia ES, et al.: Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. J Hepatol 2018 May, 68:895–903.
https://www.ncbi.nlm.nih.gov/pubmed/29221887

Minichini C, Starace M, De Pascalis S, et al.: HCV-genotype 3h, a difficult-to-diagnose sub-genotype in the DAA era. Antivir Ther 2018 Mar.
https://www.ncbi.nlm.nih.gov/pubmed/29504510

Omar H, El Akel W, Elbaz T, et al.: Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. AlimentPharmacolTher 2018 Feb, 47:421–431.
https://www.ncbi.nlm.nih.gov/pubmed/29193226

Palanisamy N, Kalaghatgi P, Akaberi D, et al.: Worldwide prevalence of baseline resistance-associated polymorphisms and resistance mutations in HCV against current direct-acting antivirals. Antivir Ther 2018 May.
https://www.ncbi.nlm.nih.gov/pubmed/29745936

Papatheodoridis GV, Hatzakis A, Cholongitas E, et al.: Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe. J Viral Hepat. 2018 Mar;25 Suppl 1:6-17.
https://www.ncbi.nlm.nih.gov/pubmed/29508946

Petta S, Adinolfi LE, Fracanzani AL, et al.: Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. J Hepatol. 2018 Jul. pii: S0168-8278(18)30132-6.
https://www.ncbi.nlm.nih.gov/pubmed/29505844

Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):383-403.
https://www.ncbi.nlm.nih.gov/pubmed/29599078

Puoti M, Foster GR, Wang S, et al.: High SVR12 with 8-week and 12-week Glecaprevir/Pibrentasvir: Integrated Analysis of HCV Genotype 1-6 Patients Without Cirrhosis. J Hepatol 2018 Mar
https://www.ncbi.nlm.nih.gov/pubmed/29551706

Smith D, Magri A, Bonsall D, et al.: Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors. Hepatology 2018 Feb,
https://www.ncbi.nlm.nih.gov/pubmed/29425396

Sorbo MC, Cento V, Di Maio VC, et al.: Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. Drug Resist 2018 Mar, 37:17–39.
https://www.ncbi.nlm.nih.gov/pubmed/29525636

Starace M, Minichini C, De Pascalis S, et al.: Virological patterns of HCV patients with failure to interferon-free regimens. J Med Virol. 2018 May;90(5):942-950
https://www.ncbi.nlm.nih.gov/pubmed/29315640

Vermehren J, Park JS, Jacobson I, et al.: Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J Hepatol. 2018 Jul
https://www.ncbi.nlm.nih.gov/pubmed/30006068

2017

AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C.
http://www.hcvguidelines.org
Antonucci F, Cento V, Sorbo MC, et al.: HCV-RNA quantification in liver bioptic samples and extrahepatic compartments, using the abbott RealTime HCV assay. J Virol Methods. 2017 Aug;246:1-7.
https://www.ncbi.nlm.nih.gov/pubmed/28408312

Bartlett SR, Grebely J, Eltahla AA, et al.: Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review. Hepatol Commun. 2017 May 22;1(5):379-390.
https://www.ncbi.nlm.nih.gov/pubmed/29404466

Calvaruso V, Craxì A.: HBV recurrence after HCV clearance on DAAs: Sometimes they come back. J Hepatol. 2017 Nov;67(5):898-901.
https://www.ncbi.nlm.nih.gov/pubmed/28864279

Cento V, Nguyen THT, Di Carlo D, et al.: Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. PLoS One. 2017 May 18;12(5):e0177352.
https://www.ncbi.nlm.nih.gov/pubmed/28545127

Cuypers L, Libin P, Schrooten Y, et al.: Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning. Infect Genet Evol. 2017 Sep;53:15-23.
https://www.ncbi.nlm.nih.gov/pubmed/28499845

Cuypers L, Vrancken B, Fabeni L, et al.: Implications of hepatitis C virus subtype 1a migration patterns for virus genetic sequencing policies in Italy. BMC Evol Biol. 2017 Mar 7;17(1):70. https://www.ncbi.nlm.nih.gov/pubmed/28270091
d’Arminio Monforte A, Cozzi-Lepri A, Ceccherini-Silberstein F, et al.: Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. PLoS One. 2017 May 17;12(5):e0177402.
https://www.ncbi.nlm.nih.gov/pubmed/28520749

Gitto S, Gamal N, Andreone P: NS5A inhibitors for the treatment of hepatitis C infection. J Viral Hepat 2017 Mar, 24:180–186.
https://www.ncbi.nlm.nih.gov/pubmed/27925362

Karampatou A, Han X, Kondili LA, et al.: Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV. J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32259-6.
https://www.ncbi.nlm.nih.gov/pubmed/28882581

Komatsu TE, Boyd S, Sherwat A, et al.: Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir. Gastroenterology 2017 Feb, 152:586–597.
https://www.ncbi.nlm.nih.gov/pubmed/27773808

Kondili LA, Gaeta GB, Brunetto MR, et al.: Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. PLoS One. 2017 Oct 4;12(10):e0185728.
https://www.ncbi.nlm.nih.gov/pubmed/28977040

Lembo T, Saffioti F, Chiofalo B, et al.: Low prevalence of hepatitis B and hepatitis C virus serum markers in a cohort of pregnant women from Southern Italy. Dig Liver Dis. 2017 Dec; 49(12):1368-1372.
https://www.ncbi.nlm.nih.gov/pubmed/28818677

Lenci I, Bosa A, Milana M, et al.: Evidence of Spontaneous Post-transplant HCV Eradication in Two Failed DAA Treatments Awaiting Liver Transplantation. Dig Dis Sci. 2017 Aug;62(8):2193-2195. https://www.ncbi.nlm.nih.gov/pubmed/28500586
Maimone S, Caccamo G, Squadrito G, et al.:A combination of different diagnostic tools allows identification of inactive hepatitis B virus carriers at a single time point evaluation. Liver Int. 2017 Mar;37(3):362-368.
https://www.ncbi.nlm.nih.gov/pubmed/27606573

Paolucci S, Premoli M, Ludovisi S, et al.: HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy. Antivir Ther 2017, 22:365–368.
https://www.ncbi.nlm.nih.gov/pubmed/28085002

Paolucci S, Premoli M, Novati S, et al.: Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs. Sci Rep. 2017 Nov 22;7(1)
https://www.ncbi.nlm.nih.gov/pubmed/29167469

Pellicelli AM, Pace Palitti V, Vignally P, et al.: Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study. Liver Int. 2017 May;37(5):653-661.
https://www.ncbi.nlm.nih.gov/pubmed/27782373

Petta S, Marzioni M, Russo P, et al.: Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol. 2017 Jun;2(6):427-434.
https://www.ncbi.nlm.nih.gov/pubmed/28497758

Puoti M, Lorenzini P, Cozzi-Lepri A, et al.: Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. Clin Microbiol Infect. 2017 Apr;23(4):267.e1-267.e4.
https://www.ncbi.nlm.nih.gov/pubmed/27956268

Struble K, Chan-Tack K, Qi K, et al.: Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration’s evaluation. Hepatology 2017 Oct, 67:482–491.
https://www.ncbi.nlm.nih.gov/pubmed/29059462

Viganò M, Perno CF, Craxì A; et al.: Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. Dig Liver Dis. 2017 Jul;49(7):731-741.
https://www.ncbi.nlm.nih.gov/pubmed/28456519

Welzel TM, Bhardwaj N, Hedskog C, et al.: Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. J Hepatol 2017 Aug, 67:224–236.
https://www.ncbi.nlm.nih.gov/pubmed/28343981

Wyles DL, Luetkemeyer AF: Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens. Top Antivir Med 2017 Jul, 25:103–109 https://www.ncbi.nlm.nih.gov/pubmed/28820725
Wyles DL: Resistance to DAAs: When to Look and When It Matters. Curr HIV/AIDS Rep 2017 Dec, 14:229–237.
https://www.ncbi.nlm.nih.gov/pubmed/29116550

Zuckerman A, Chastain CA, Naggie S: Retreatment Options Following HCV Direct-Acting Antiviral Failure. Curr Treat Options Infect Dis 2017 Dec, 9:389–402.
https://www.ncbi.nlm.nih.gov/pubmed/29242710

2016

Ceccherini Silberstein F, Di Maio VC, Aragri M, et al.: Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents. Hepatology. 2016 Mar;63(3):1058-9.
https://www.ncbi.nlm.nih.gov/pubmed/25974082

Chen ZW, Li H, Ren H, et al.: Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data. SciRep 2016 Feb, 6:20310.
https://www.ncbi.nlm.nih.gov/pubmed/26842909

Craxì A, Perno CF, Viganò M, et al.: From current status to optimization of HCV treatment: Recommendations from an expert panel. Dig Liver Dis. 2016 Sep;48(9):995-1005.
https://www.ncbi.nlm.nih.gov/pubmed/27388261

Cuypers L, Ceccherini-Silberstein F, Van Laethem K, et al.: Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. Rev Med Virol. 2016 Nov;26(6):408-434. https://www.ncbi.nlm.nih.gov/pubmed/27401933
Kartashev V, Döring M, Nieto L, et al.: New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. J Clin Virol. 2016 Aug;81:82-9.
https://www.ncbi.nlm.nih.gov/pubmed/27367545
Sarrazin C: The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 2016 Feb, 64:486–504.
https://www.ncbi.nlm.nih.gov/pubmed/26409317

2015

Lontok E, Harrington P, Howe A, et al.: Hepatitis C virus drug resistance-associated substitutions: State of the art summary. Hepatology 2015 Nov, 62:1623–1632.
https://www.ncbi.nlm.nih.gov/pubmed/26095927

2014

Di Maio VC, Cento V, Mirabelli C, et al.: Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors. Antimicrob Agents Chemother. 2014 May;58(5):2781-97.
https://www.ncbi.nlm.nih.gov/pubmed/24590484